Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

123.82 +4.52 (+3.79%)
Official Closing Price Updated: 7:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,636,444
Open 119.68
Bid (Size) 123.50 (300)
Ask (Size) 123.88 (100)
Prev. Close 119.30
Today's Range 119.68 - 124.00
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety
As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
What's going on in today's session: S&P500 movers ↗
Via Chartmill

Performance

YTD
+16.3%
+16.3%
1 Month
+15.8%
+15.8%
3 Month
+18.1%
+18.1%
6 Month
+47.2%
+47.2%
1 Year
+36.7%
+36.7%

More News

Read More
News headline image
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
Via MarketMinute
Topics Artificial Intelligence Economy
Merck & Co. Inc. (NYSE:MRK) Emerges as a Strong Dividend Contender Through Methodical Screening ↗
Via Chartmill
News headline image
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Via MarketMinute
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
Via Finterra
Topics Lawsuit
News headline image
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
From Merck & Co., Inc. and Mayo Clinic
Via Business Wire
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
Via Finterra
Topics Economy Intellectual Property
News headline image
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗
Via Stocktwits
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 123.82
When was Merck & Co last traded?
The last trade of Merck & Co was at 02/27/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 313.43B
How many shares of Merck & Co are outstanding?
Merck & Co has 313B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.